Postmenopausal Hormone Therapy: : Differential Impact of Dose and Regimenson Hemostasis and Inflammation by Eilertsen, Anette Løken
 
 
 
 
Postmenopausal Hormone Therapy:
Differential Impact of Dose and Regimens
on Hemostasis and Inflammation
by
Anette Løken Eilertsen, MD
Department of Hematology
Hematological Research Laboratory
Ullevål University Hospital Trust, Oslo, Norway
Faculty of Medicine, University of Oslo, 2009
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© Anette Løken Eilertsen, 2009 
 
 
Series of dissertations submitted to the  
Faculty of Medicine, University of Oslo 
No. 821 
 
ISBN 978-82-8072-950-7 
 
 
All rights reserved. No part of this publication may be  
reproduced or transmitted, in any form or by any means, without permission.   
 
 
 
 
 
 
 
 
Cover: Inger Sandved Anfinsen. 
Printed in Norway: AiT e-dit AS, Oslo, 2009.   
 
Produced in co-operation with Unipub AS.  
The thesis is produced by Unipub AS merely in connection with the  
thesis defence. Kindly direct all inquiries regarding the thesis to the copyright  
holder or the unit which grants the doctorate.   
 
Unipub AS is owned by  
The University Foundation for Student Life (SiO) 
 3 
Table of Contents
Acknowledgment            7 
Abbreviations             9 
Summary           11 
List of papers           13 
1. Introduction          15 
1.1. Menopause           15 
1.1.1. Introduction        15 
1.1.2. Changes in hormones       15 
1.2. Postmenopausal Hormone therapy       16 
1.2.1. History         16 
1.2.2. Estrogens         17 
1.2.3. Progestagens        18 
1.2.4. Tibolone         18 
1.2.5. Raloxifene        19 
1.3. Hemostasis           19 
1.3.1. Normal hemostasis       19 
1.3.2. The cell based model of coagulation     20 
1.3.3. Regulation of coagulation      22 
1.3.4. Fibrinolysis        23 
1.4. Endothelial function and dysfunction      25 
1.4.1. Endothelial function and dysfunction     25 
1.4.2. Cell adhesion molecules, endothelial, and inflammatory markers 26 
1.5. Venous thrombosis, epidemiology and risk factors    27 
1.5.1. Epidemiology        27 
1.5.2. Inherited and acquired risk factors for venous thrombosis   28 
1.5.3. Hemostatic factors and risk of venous thrombosis   28 
1.6. Atherothrombosis, epidemiology and risk factors     29 
1.6.1. Epidemiology and risk factors       29 
1.6.2. Atherosclerosis and inflammation     29 
1.7. Hormone therapy and risk of venous thrombosis    30 
 4 
1.8. Hormone therapy and risk of atherothrombosis    30 
1.9. Menopause and changes in hemostatic factors     31 
1.10. Hormone therapy and effects on coagulation     31 
1.10.1. Markers of activated coagulation     31 
1.10.2. Coagulation factors       32 
1.10.3. Coagulation inhibitors       32 
1.10.4. Fibrinolysis        33 
1.11. Hormone therapy and effects on endothelium and inflammation  33 
2. Aims and hypotheses         39 
3. Methods           41 
3.1. Study design, study subjects, intervention      41 
3.1.1. Raloxifene, estrogen and tibolone (RET) study    41 
3.1.2. The Estrogen in Venous Thromboembolism Trial (EVTET)  41 
3.1.3. The Estrogen Women Atherosclerosis (EWA) study   42 
3.2. Data collection         42 
3.3. Laboratory assays/Measurements       42 
3.4. Statistics           43 
3.4.1. Demographic variables       43 
3.4.2. Descriptive statistics       43 
3.4.3. Significance testing       43 
3.4.4. Correlation and regression models     44 
3.4.5. Power calculation in the RET-study     44 
3.4.6. Statistical packages       44 
3.5. Ethical aspects         44 
4. Main results            47 
4.1. Demographic characteristics in the RET-study     47 
4.2. Impact on markers of activated coagulation (paper I)    48 
4.3. Mechanisms for activated coagulation; Impact on coagulation factors, coagulations 
inhibitors and fibrinolysis (paper II)       48 
4.4. Impact on the APC-system (paper III)      49 
4.5. Impact on markers of inflammation (paper IV)     50 
4.6. Impact of oral and transdermal therapy in women with vascular disease (p. V) 50 
 5 
5. General discussion         53 
5.1. Methodological considerations       53 
5.1.1. Study design         53 
5.1.2. Study population        54 
5.1.3. Intervention        54 
5.1.4. Measurements        55 
5.1.5. Statistical aspects       56 
5.2. Discussion of main findings        56 
5.2.1. Impact of hormone therapy on activation of coagulation  56 
5.2.2. Impact of tibolone and raloxifene on activation of coagulation 57 
5.2.3. Impact of hormone therapy on coagulation    57 
5.2.4. Impact of tibolone and raloxifene on coagulation   57 
5.2.5. Impact of hormone therapy on inflammation    58 
5.2.6. Impact of tibolone and raloxifene on inflammation   58 
5.2.7. Proposed mechanism of activation of coagulation   59 
5.2.8. Proposed mechanism of inflammation     59 
5.2.9. Link between coagulation and inflammation    60 
5.3. Clinical implications         60 
5.3.1. Biochemical markers and clinical importance    61 
5.3.2. Relation to dose of hormone therapy     61 
5.3.3. Impact of progestin       62 
5.3.4. Tibolone and raloxifene       62 
5.3.5. C-reactive protein –a predictor of venous thrombosis?  63 
5.3.6. Relation of route of administration     63 
6. Main Conclusions         65 
7. Future perspectives         67 
8. References          69 
9. Papers            
 6 
 7 
Acknowledgments 
The present work was carried out at the Hematological Research Laboratory, Department of 
Hematology, at Ullevål University Hospital Trust (UUS) from 2002 to 2008. During this 
period, I was a Research Fellow at the University of Oslo.  
I wish to express my most sincere gratitude to my principal supervisor Professor Per 
Morten Sandset (MD, PhD), who initiated the project and gave me the opportunity to do 
research. It has been a privilege to experience his enthusiasm and his knowledge in the fields 
of research and the coagulation system. I am very thankful for his excellent support and the 
constructive advice, comments, and discussions during the preparation of the manuscripts. 
Professor Erik Qvigstad (MD, PhD) at the Department of Gynecology, being my co-
supervisor, has inspired me through his positive attitude, his flexibility and his belief in the 
project. I am thankful for his help in initiating the RET-study. Erik Qvigstad, Anne Flem 
Jacobsen (MD, PhD) and Kirsten Hald (MD) made major contributions in the RET-study by 
carrying out all the gynecological examinations. 
I am also grateful to Professor Per Skaane (MD, PhD) at the Department of Radiology 
for facilitating the mammographic examinations and for his scientific advice. I gratefully 
acknowledge the support from Randi Gullien, Anne Marie Haakull and Inger Eide at the 
Department of Radiology for organizing the mammographic examinations. I am also grateful 
for the assistance from Haakon Sandset in organizing the mammographic data and for his 
good spirits. 
Professor Ingrid Os (MD, PhD) and Dr. Else Høibraaten (MD, PhD) kindly introduced 
me to the field of postmenopausal hormone therapy by allowing me to continue their work 
in EWA and EVTET- projects. In addition, Else Høibraaten made substantial contribution to 
conception and design of the RET-study. I appreciate their generosity and their scientific 
advice.  
Furthermore, I thank the other PhD-students, former PhD-students and research 
colleagues and Professors at the Hematological Research Laboratory, UUS for their good 
spirit, a gentle atmosphere and for having provided a friendly and skilled forum to discuss 
both research and other issues. In alphabetical order; Bjørn Bendz, Astrid Bergrem, Anders 
E.A. Dahm, Tone Enden, Nina Gulbrandsen, Per Ole Iversen, Anne Flem Jacobsen, Eva Marie 
Jacobsen, Torstein Jensen, Ann Kristin Kvam, Sigurd Liestøl, Helene Negaard, Else Charlotte 
 8 
Sandset, Grethe Skretting, Benedicte Stavik, Lena Tjeldhorn and Finn Wisløff. I especially 
acknowledge the invaluable assistance and skilful laboratory support from Marie-Christine 
Mowinckel, Trine Opstad Andersen, Kaia Haugbro, Brit Steinsvik, Meliha Turkovic and Marie 
Skogstad. Thanks to Anne Været, Renate Ruyter, Siri Heier, Mette Carlsen, Ann Døhli, and 
Karl Gravem for their hospitality and friendly encouragements.  
Professor Leiv Sandvik (PhD), at the center of clinical research, has introduced me to 
scientific approach and statistical methodology. His constructive advice and his critical 
comments have been of great importance both during preparation of the manuscripts and in 
completion of this thesis. I will also thank him for all the challenging discussions and for 
being a supportive friend. 
I am indebted to all the women who participated in the RET-study, the EVTET and 
EWA-study, without their contribution this work could not have been accomplished. 
The RET-study was financially supported by an unconditional grant from NovoNordisk 
Scandinavia. I am very thankful for this support, which was made possible by Medical 
Director Egil Wickstrøm. 
I was encouraged to leave clinical work and do research by Hege Folger (MD), my 
clinical supervisor at Akershus University Hospital. I am thankful for her faith in me. 
Professor Magne Osnes (MD, PhD) and Marit Knutsen at the Faculty of Medicine have 
provided excellent working conditions in the teaching part of my work. Many thanks for their 
support and enthusiasm.  
I thank my husband Petter for his generosity and our wonderful children Jens, Ola 
and Elise for reminding me of the most important things in life. 
 
 
 9 
Abbreviations
a  activated 
APC  activated protein C 
APTT  activated partial thromboplastin time 
AT  antithrombin 
CAD  coronary artery disease 
CAT  calibrated automated thrombogram 
CEE  conjugated equine estrogen 
CHD  coronary heart disease 
CI95  95% confidence interval 
CRP  C-reactive protein 
CV  Coefficient of variation 
CVD  cardiovascular disease 
DVT  deep vein thrombosis 
E2  17-estradiol 
EE2  17-ethinylestradiol 
ELISA  enzyme-linked immunosorbent assays 
ER  estrogen receptor 
ETP  endogenous thrombin potential 
EVTET  Estrogen in Venous ThromboEmbolism Trial 
EWA  Estrogen Women Atherosclerosis 
F  factor 
F1+2  prothrombin fragments 1+2 
FSH  follicle stimulating hormone 
HT  hormone therapy 
ICAM-1 intercellular adhesion molecule-1 
INH  inhibin 
LH  luteinizing hormone 
Lp(a)  lipoprotein-a 
MCP  monocyte chemoattractant protein 
MP  micronized progesterone 
 10 
MPA  medroxyprogesterone acetate 
nAPCsr normalized APC sensitivity ratio 
NETA  northisterone acetate 
OC  oral contraceptive 
PAI-1  plasminogen activator inhibitor- 1 
PAR  protease activated receptor 
PC  protein C 
PE  pulmonary embolism 
PS  protein S 
PT  prothrombin time 
RCT  randomized clinical trials 
SERM  selective estrogen receptor modulators 
RET  Raloxifene Estrogen Tibolone 
SPSS  Statistical Package for the Social Sciences 
TAFI  thrombin activated fibrinolysis inhibitor 
TAT  thrombin-antithrombin  
TF  tissue factor 
TFPI  tissue factor pathway inhibitor 
TGF   transforming growth factor  
TM  thrombomodulin 
TNF  tumor necrosis factor  
tPA  tissue plasminogen activator 
VT  Venous thrombosis 
VWF  von Willebrand factor 
 
 
 11 
Summary
Postmenopausal hormone therapy (HT) is currently mainly used for a limited time-period to 
relieve climacteric symptoms and for the prevention of osteoporosis. Over the last decade, 
reports have focused on adverse effects of HT, such as increased risk of cardiovascular 
disease (CVD), venous thrombosis (VT), and breast cancer. Several studies have shown that 
oral HT containing estrogen in conventional doses is associated with an increased risk of VT 
and an activation of coagulation. Moreover, it has recently been shown that even minor 
changes in clotting factors and coagulation inhibitors within normal ranges may account for 
such activation. The aim of this thesis was to compare the impact of four HT regimens on 
markers of activated coagulation and to identify potential mechanisms for activated 
coagulation by analyzing markers of vascular disease. In particular, we wanted to investigate 
whether lower dose of HT decreased impact on the markers. 
We have found that the four regimens had markedly different impact on markers of 
activated coagulation, coagulation factors, coagulation inhibitors, fibrinolytic factors, and on 
markers of inflammation. The conventional- and low-dose HT groups generally showed 
similar effects, with more pronounced effects in the conventional-dose HT group. In women 
with previous thrombosis, oral HT containing estradiol was associated with a marked and 
rapid increase in CRP, whereas transdermal treatment was not. Moreover, HT appeared to 
reduce levels of endothelial markers both in healthy women and in women with high risk of 
thrombosis. 
These findings are probably clinically relevant, and indicate that low-dose HT has a 
more favorable risk to benefit profile than conventional-dose HT. We believe that the 
differential effects of the regimens on coagulation and other markers reflect a differential 
risk of VT. Moreover, in women with high risk of thrombosis, the differential effects on CRP 
of oral and transdermal HT suggest that transdermal therapy is safer. 
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1. Introduction
1.1 Menopause  
The word “menopause” is derived from men and pausis and is a description of the 
physiological event when menstruation ceases to occur. The word “climacteric” is a Greek 
derivation of “the ladder” or “steps of a ladder”, and is defined as the whole period with 
decreasing hormone production, which usually has duration of five years on each side of the 
menopause. Natural menopause is commonly defined as age at the last menstrual period, 
which is determined retrospectively, when a woman has experienced 12 consecutive months 
of amenorrhoea without any obvious intervening cause. Mean age at natural menopause in 
Caucasian populations is between 50-52 years [1-3]. Since average age of menopause has 
been fairly constant over time, and women in most societies live longer, a longer period of a 
woman`s life is postmenopausal. 
Menopause is a physiological event that occurs in all women who reach midlife, and 
is a complex transition involving biological, physiological, social, and cultural factors. 
Climacteric symptoms refer to an increase of vasomotor symptoms, such as “hot flushes” 
and night sweats, insomnia, and urogenital atrophy [4-7]. Many other symptoms, i.e., 
irregular menstrual bleeding, osteoporosis, cardiovascular disease (CVD), depressed mood, 
and irritability are associated with menopause, but are not necessarily correlated to 
estrogen levels. 
 
1.1.2 Changes in hormones 
In the fertile period, almost all active estrogen, i.e., 17estradiol (E2), is produced by 
granulosa and theca cells in ovaries and their luteinized derivates [8]. During menstrual 
cycles, the production of E2 varies cyclically and reaches peaking levels just before ovulation. 
After the follicle ruptures at ovulation, the corpus luteum secretes progesterone, but small 
amounts are also produced by the adrenal glands. The cyclical pattern is regulated by 
positive and negative feedback mechanisms, i.e., complex interactions between hormones 
from the hypothalamus, the pituitary and the ovaries. During the follicular phase of the 
cycle, levels of E2 stimulate secretion of gonadotrophins, while progesterone and inhibin B 
(INH-B) contributes to control of luteinizing hormone (LH) and follicle stimulating hormone 
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(FSH) secretion, respectively. In the luteal phase both E2 and progesterone regulate the 
gonadotrophins, while inhibin A (INH-A) are involved in the FSH secretion [9].  
The progressive loss of follicles of the ovaries leads to an absence of follicular 
function and a permanent cessation of menstruation. The serum patterns of ovarian and 
pituitary hormones alter as the menopause approaches, and a decreased secretion of INH-B 
from the granulosa-cells leads to an initial slow rise in FSH. As the follicle number 
progressively decreases, the reduced levels of INH-B and E2 lead to a more marked increase 
in the gonadotrophins, increased level of FSH and a later rise in LH [10]. 
Estrone (E1), which is mainly produced in the adrenal cortex, is the dominant 
estrogen in postmenopausal women. Moreover, levels of progesterone and E2 are very low 
and most of the E2 is formed by extragonadal conversion from androstendion and 
testosterone [8].  
1.2 Postmenopausal hormone therapy 
1.2.1 History 
Various hormone preparations have been used in the treatment of climacteric symptoms 
since the end of the 19th century, and different estrogen formulations have for more than 60 
years been approved by the US Food and Drug Administration as such treatment [11]. HT 
had increasing popularity for decades, until studies in the mid 1970s revealed that treatment 
with estrogen alone was associated with an increased risk of uterine cancer [12;13]. It has 
later been shown that by combining estrogen with a progestin, the increased risk of 
endometrial hyperplasia and uterine cancer was avoided [14;15]. It is therefore 
recommended that estrogen to be given in combination with a progestin in women with a 
preserved uterus. The increasing use of HT in the 1980s was probably related to publication 
of reports showing effective protection of estrogen in preventing bone-loss [16]. 
Epidemiological studies showing reduced risk of CVD in estrogen-users further increased the 
popularity in the 1990s [17;18]. The large randomized clinical trials (RCT): Heart 
Estrogen/progestin Replacement Study (HERS) and Women’s Health Initiative (WHI) have 
reported potential greater harm than benefit of combined estrogen/progestin treatment in 
conventional doses, both in healthy women and in women with vascular disease [19;20]. 
Moreover, the Estrogen in Venous Thromboembolism Trial (EVTET) revealed an increased 
risk of recurrent VT by use of HT in women with a history of VT [21]. These findings altered 
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the indication for use in clinical practice and caused a profound decrease in the use of HT. 
Currently, HT is mostly used for a limited period to relieve climacteric symptoms, and for the 
prevention of osteoporosis. 
HT was initially administered as oral estrogen, but since the 1980s new forms of 
application such as patches, gels, nasal spray, vaginal rings, and vaginal tablets became 
available [11]. Various formulations of estrogens, progestins, and estrogen-progestin 
combinations have been approved for treatment of climacteric symptoms. HT can be 
administered continuously, with a fixed daily dose of estrogen and progestin, or with 
intermittent administration of a progestin. In perimenopausal women, intermittent 
administration of progestin is preferable in order to regulate genital bleeding.  
Tibolone is a synthetic steroid compound with estrogenic, progestogenic and 
androgenic properties. It has been used in Europe since the beginning of the 1980ies, and 
the indications for use are similar to conventional HT: prevention of postmenopausal 
osteoporosis and treatment of climacteric symptoms [22]. 
Selective estrogen receptor modulators (SERMs) have also been available for 
decades. The interest in the SERMs increased after recognition of their selective agonist and 
antagonist effects on various estrogen target tissues. Tamoxifene was developed as an 
antiestrogen for the treatment of breast cancer. It maintains bone density, but stimulates 
the endometrium [23] which implies an increased risk of endometrial cancer [24]. Raloxifene 
is an alternative to estrogen in prevention and treatment of osteoporosis. 
 
1.2.2 Estrogens 
The naturally occurring estrogens; E2, E1 and estriol (E3), are C18 steroid hormones derived 
from cholesterol. In addition to the naturally occurring estrogens, wide ranges of natural and 
synthetic substances possess estrogenic activity. Estrogens have multiple biological effects 
that are determined by the structure of the hormone, the subtype of the estrogen receptor 
(ER) involved, and the tissue distribution of the receptors. The different estrogen ligands 
have differential affinity for the ER [8]. Many types of estrogens and estrogen-derivatives are 
utilized in postmenopausal HT and oral contraceptives (OC). Conjugated equine estrogens 
(CEE) are most commonly used in the US and were tested in the WHI and HERS studies. In 
the Northern Europe E2 is mainly used. The different types of estrogens are shown in table 
1. 
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1.2.3 Progestagens (progestogens or gestagens) 
Progestagens are steroid hormones that produce effects similar to those of progesterone, 
the only natural progestagen. Progesterone is the most potent progestagen. The function of 
progesterone in the fertile woman is to prepare the genital tract for reception and 
maturation of the fertilized ovum and to maintain pregnancy. All other progestagens are 
synthetic and are often referred to as progestins. Progestagens differ in affinity for the 
progesterone receptor and have androgenic, antiandrogenic, anti-mineralocorticoid, 
estrogenic and anti-estrogenic properties. Progestins can be classified according to source of 
the derivative; 17-hydroxyprogesterone (structural similarities with progesterone) and 
19-nortestosterone (structural similarities with testosterone) [25]. Norethisterone acetate 
(NETA) is the most commonly used progestin in HT in Northern Europe, while 
medroxyprogesterone acetate (MPA) and micronized progesterone (MP) are most 
commonly used in the US. The different progestagens are shown in table 1. 
 
ESTROGENS PROGESTAGENS 
Natural Synthetic 17--OH progesterone 19-nortestosterones 
    
HUMAN STEROIDS PREGNANES ESTRANES 
Estradiol Etinyl estradiol Medroxyprogesteronacetate Norethisterone 
Estriol Mestranol Megestrole acetate Norethisterone acetate 
Esterone  Cyproterone acetate Lynestrenole 
  Dydrogesterone  
ESTERS NON-STEROIDS  GONANES 
Estradiol-valerate Dienestrole  Norgestrel 
Estrone sulphate   Levonorgestrel 
   Desogestrel 
   Gestodene 
CONJUGATED OTHER  Norgestimate 
Sodium estrone-sulphate Tibolone   
Sodium equiline-sulphate    
Sodium equileine-sulphate    
 
Table 1 Types of Estrogens and Progestagens 
 
1.2.4 Tibolone 
Tibolone has been classified as a selective tissue estrogenic activity regulator (STEAR) [26]. It 
is structurally related to 19-nortestosterone derivatives and is after oral administration 
converted into three primary active agents: 3--hydroxy-tibolone, 3--hydroxy-tibolone and 
-4-tibolone [27]. The specific effects of tibolone in different tissues depend on the presence 
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of one of its active metabolite and its binding and activation of the associated receptor. The 
hydroxyl-tibolone metabolites exert estrogenic effects on the bone, vagina, and climacteric 
symptoms. The progestogenic activities of the 4-isomer prevent stimulation of the 
endometrium, whilst the androgenic activities may play a role in the liver and brain. RCTs 
have shown beneficial effects of tibolone on prevention of bone loss, and tibolone is 
associated with a low incidence of vaginal bleeding [22].  
 
1.2.5 Raloxifene 
SERMs are a group of compounds that is structurally related, but chemically different from 
estrogen. They lack steroidal structure, but possess a tertiary structure that allows them to 
bind to the ER. SERMs exert selective estrogen agonistic or antagonistic effects, depending 
on the target tissue [23]. 
Raloxifene hydrochloride is a benzothiophene that binds to ER, and is classified as a 
SERM. In postmenopausal women, raloxifene increases bone mineral density and reduces 
the risk of vertebral fractures [28]. It is approved for use in prevention and treatment of 
osteoporosis in several countries, whilst it is not indicated for the treatment of climacteric 
symptoms due to an anti-estrogenic effect in hypothalamus. Raloxifene has estrogen-agonist 
effects on lipoproteins and lipid metabolism, whereas estrogen antagonistic effects are seen 
in breast and uterus. It is associated with a reduced risk of breast cancer in osteoporosis 
prevention trials [29;30] and in women with increased risk of CVD [31].  
1.3 Hemostasis 
1.3.1 Normal hemostasis 
Hemostasis describes the biological process responsible for maintaining proper blood flow 
and the physiological cessation of bleeding after vascular injury. The process involves the 
vessel wall, platelets, and plasma-proteins. At the site of tissue damage, platelets circulating 
in the blood rapidly adhere to collagen and other extracellular matrix components of the 
subendothelium. The platelets subsequently recruit additional platelets and leukocytes to 
form the platelet plug. The coagulation system is activated by tissue factor (TF), which is 
exposed to circulating blood either by vascular damage or by production and exposure on 
the surface of blood monocytes. When coagulation is initiated, it proceeds through a series 
of activation steps that ends in the generation of thrombin. Thrombin cleaves fibrinogen to 
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generate fibrin. Concomitant activation of naturally occurring anticoagulants and the 
fibrinolytic system are important regulatory mechanisms of clot formation. This delicate 
balance can be disrupted resulting in thrombosis or abnormal bleeding [32]. 
Over the last century, several theories for understanding the underlying mechanisms 
of hemostasis have been proposed. The biochemical era of blood coagulation began with the 
theories of Schmidt and Morawitz who suggested that activation of prothrombin to 
thrombin, by thromboplastins (later named TF), and conversion of fibrinogen to fibrin by 
thrombin, were important reactions involved in clot formation. The original description of 
the coagulation process as a “cascade” or “waterfall” reaction was based on circumstantial 
evidence and the discovery of coagulation proteins in the mid 20th century [33]. These 
models have later been modified. In a later version, the interactions between the 
coagulation proteins was outlined in two distinct activation pathways; the extrinsic (TF-
induced) pathway and intrinsic (contact activation) pathway converging on a “common” 
pathway, with thrombin generation as the end-point of the reactions. The components of 
the extrinsic pathway are measured in the prothrombin time (PT) assay, whilst the factors in 
the intrinsic pathway are measured in the activated partial thromboplastin time (APTT) 
assay. Although these models have been useful in clinical coagulation laboratory tests, they 
have been shown to be insufficient in explaining the connection between coagulation factor 
deficiencies and clinical phenotypes (e.g., the serious bleeding tendency in patients deficient 
of FVIII or FIX although the extrinsic pathway was intact). Models that are more recent 
reflect the coagulation process in vivo, involving the vessel wall, platelets, and plasma-
proteins and are consistent with clinical conditions. Our contemporary understanding of 
hemostasis is that coagulation occurs on specific cell surfaces in distinct, but overlapping 
steps; initiation, amplification and propagation [34;35]. The coagulation process starts on TF-
bearing cells and proceeds on the surface of activated platelets. 
 
1.3.2 Cell based model of coagulation 
The initiation phase is triggered when TF is exposed to blood. TF is a transmebrane 
glycoprotein that is constitutively expressed in cells of the subendothelium or extravascular 
tissues and is exposed to plasma upon vascular injury. Moreover, synthesis of TF is inducible 
in monocytes and other cells by a number of stimuli and may be expressed in microparticles 
from different origins. The circulating factor (F)VII/FVIIa in plasma binds to TF forming the 
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TF/FVII(a) complex (figure 1). The activated TF/FVIIa complex cleaves zymogen forms of FIX 
and FX to their active enzyme forms (FIXa and FXa). In plasma, the serine protease inhibitors 
antithrombin (AT) and TF pathway inhibitor (TFPI) rapidly inactivate FXa, whereas FXa 
localized on a phospolipid membrane surface, e.g., in proximity of TF, is relatively protected 
from inactivation. FIXa is more stable and can dissociate from the TF-bearing phospholipid 
environment and dock on a nearby, activated platelet or another cell surface. FIXa is not 
inhibited by TFPI and are only slowly inactivated by AT. FXa that remains on the TF-
phospholipid surface can associate with FVa to form the prothrombinase complex to 
generate small amounts of thrombin. FVa derives from several sources; circulating FV can be 
activated by thrombin or FXa, or secreted from the activated platelet.  
The small amounts of thrombin produced in the initiation phase have several 
important functions in the amplification phase. Low concentration of thrombin fully 
activates platelets adhering to the site of injury. On the surface of the platelet, thrombin 
activates FV, FXI, and FVIII by cleaving it from von Willebrand factor (VWF). 
In the propagation phase, procoagulant complexes assemble on the surface of the 
activated platelets to accelerate thrombin generation. FIXa binds to FVIIIa on the surface of 
the activated platelets to form the FIXa/VIIIa complex (tenase), which converts FX to FXa. 
Moreover, platelet-bound FXIa can activate FIX to form more tenase. FXa then rapidly 
associates with FVa to form the prothrombinase-complex, which cleaves prothrombin to 
thrombin and prothrombin fragments 1+2 (F1+2) on the platelet surface. F1+2 is thereby a 
marker of thrombin generation (figure 2). Thrombin then catalyzes the conversion of 
fibrinogen to form soluble fibrin monomers, which spontaneously polymerizes into non-
covalently insoluble fibrin-polymers. Finally, the fibrin-clot is stabilized by cross-linking by 
FXIIIa, which is activated by thrombin (figure 2). 
Thrombin is involved in the regulation of proinflammatory processes including the 
expression of leukocyte adhesion molecules on endothelial cells, leukocyte chemotaxis, 
activation of platelets, and it has properties as a growth factor [36].  
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Figure 1 Schematic overview of the regulation of coagulation 
AT is the main inhibitor of thrombin, but also inactivates FXa, FIXa, FXIa (blue color), and FVIIa bound to TF. 
TFPI inhibits both FXa and the TF/VIIa complex. Initially TFPI binds to FXa, and then the TFPI/FXa complex binds 
to the TF/FVIIa complex forming a quaternary TFPI/FXa/TF/FVIIa complex (red color). The PC system exerts its 
anticoagulant effect by regulating the activity of FVIIIa and FVa, which function in the tenase and the 
prothrombinase-complex, respectively (green color). 
 
 
1.3.3 Regulation of blood coagulation 
Several naturally occurring anticoagulant pathways regulate the activity of the coagulation 
system. The most important pathways include a series of anticoagulant proteins and 
cofactors which bind to activated coagulation factors and down-regulate their activity [37].  
AT is a serine protease inhibitor that, in addition to be the important inhibitor of 
thrombin, can inhibit activated coagulation serine proteases, including FIXa, FXa, and FXIa 
(figure 1), and also FVIIa bound to TF. The inhibitory activity of AT is accelerated by specific 
interactions with the cofactors heparin and heparan sulphate proteoglycans. The heparan 
sulphate on the endothelium and subendothelium localize AT activity to the vessel wall and 
maintain its natural non-thrombogenic properties [38]. AT has also been shown to have anti-
inflammatory functions, probably mediated by signaling through heparan sulphate on 
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endothelial and leukocyte cell surfaces. Thrombin bound to AT, i.e. TAT-complex, is both a 
marker of generated thrombin and its inactivation by AT (figure 2).  
TFPI, the physiological inhibitor of TF, is mainly produced in endothelial cells and 
platelets. TFPI is found in different forms and is localized in association with endothelial cells, 
and platelets. It is present in the blood in a free form or bound to lipoproteins. TFPI inhibits 
both FXa and the TF-VIIa complex. Initially, TFPI binds to FXa, and then the TFPI/FXa complex 
binds to the TF/FVIIa complex forming a quaternary TFPI/FXa/TF/FVIIa complex [39]  
The protein C (PC) anticoagulant pathway is a major regulatory mechanism that is 
activated by the thrombin-thrombomodulin (TM) complex [40]. Activation of PC is initiated 
by the binding of thrombin to TM and endothelial protein C receptor (EPCR) on the 
endothelial surface and this complex activates PC. When activated PC (APC) dissociates from 
the EPCR, it interacts with its cofactor protein S (PS) on membrane surfaces to catalyze the 
inactivation of FVa and FVIIIa, the important cofactors of the tenase and the 
prothrombinase-complexes (figure 1) [41]. 
APC resistance is a phenomenon characterized by poor response to APC, i.e., low 
sensitivity to APC, when APC is added to plasma ex vivo. Inherited APC-resistance is caused 
by the FVLeiden mutation, which is due to a specific point mutation in exon 10 (G1691A shift) 
of the FV gene. The mutation predicts an arginine to glutamine substitution in position 506 
of the mature FV molecule. Since the 506 position of the FV molecule is one of three sites at 
which APC cleaves and inactivates FVa, the mutation delays inactivation of FVa [42]. An 
acquired form of APC resistance may be seen in certain conditions, such as pregnancy or 
exogenous hormone therapy, i.e., OC and postmenopausal HT use [43;44]. APC resistance 
can be measured in plasma using an APTT based assay, but more recently new methods 
based on thrombin generation, expressed as normalized APC sensitivity ratios (nAPC-SR) 
have been developed (see Methods and Discussion) [45]. 
 
1.3.4 Fibrinolysis 
The fibrinolytic system is a series of enzymes responsible for the proteolytic elimination of 
fibrin. The activity of the fibrinolytic system limits clot formation and determines the 
persistence of the thrombi in the vascular system. 
Plasmin, the key enzyme of fibrinolysis, degrades the fibrin clot into fibrin-fragments 
known as fibrin-degradation products (FDP). D-dimer is a specific FDP that contains the 
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cross-linked region of fibrin. D-dimer is thus a marker of fibrin formation and subsequent 
degradation of fibrin by plasmin. Moreover, increased D-dimer is a marker of activated 
coagulation and ongoing fibrinolysis (figure 2). Plasmin is formed by activation of the 
circulating inactive zymogen plasminogen. The main activator is tissue plasminogen activator 
(tPA), a serine protease synthesized, stored, and released from endothelial cells. Urokinase 
plasminogen activator (uPA) can also activate plasminogen. These plasminogen activators 
are inhibited by plasminogen activator inhibitor-1 (PAI-1). PAI-1 is produced in many cell 
lines, including endothelial cells, and release of PAI-1 can by stimulated by many different 
compounds, including cytokines, thrombin, and endotoxins [46]. Thrombin, when bound to 
TM, can activate thrombin activable fibrinolysis inhibitor (TAFI), also known as 
procarboxypeptidase B. TAFI inhibits fibrinolysis through several mechanisms. Activated TAFI 
(TAFIa, carboxypeptidase B) removes N-terminal lysine residues of fibrin. These lysine 
residues are important binding-sites for tPA and plasmin(ogen). TAFIa thereby prevents 
fibrinolysis and enhances clot resistance [47]. 
 
 
 
Figure 2 Markers of activated coagulation 
D-dimer is a marker of fibrin formation and consequent degradation of fibrin by plasmin. Increased D-dimer is 
thus a marker of activated coagulation and ongoing fibrinolysis. F1+2 is formed by the cleavage of prothrombin 
and is a marker of thrombin generation, whereas thrombin bound to AT forming TAT-complexes is both a 
marker of generated thrombin and its inactivation by AT. 
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Figure 3 Schematic overview of the fibrinolysis 
Plasmin degrades fibrin into fibrin-degradation products (FDP). D-dimers are specific crosslinked FDPs and 
specific for fibrin. Fibrinolysis is activated by tissue plasminogen activator (tPA), which cleaves plasminogen to 
plasmin. Fibrinolysis is inhibited by inhibitors, including plasminogen activator inhibitor-1 (PAI-1). Thrombin, 
when bound to thrombomodulin (TM), can activate thrombin-activable fibrinolysis inhibitor (TAFI), which can 
inhibit fibrinolysis through different mechanisms. 
1.4 Endothelial functions and dysfunction 
Research during the last decades has revealed that the vascular endothelial cells by 
secretion or surface expression of a series of specific molecules are involved in maintaining 
vascular homeostasis. Under normal conditions the endothelium prevents leukocyte and 
platelet adhesion to the vascular wall, displays anticoagulant and fibrinolytic properties, 
inhibits proliferation of vascular smooth muscle cells, and controls vasoconstriction. 
Localized alteration or loss in these functions, induced by a variety of stimuli, lead to 
endothelial dysfunction, increasing the adhesiveness of the endothelium i.e. leukocyte 
adherence and platelet activation. The injury also induces the endothelium to have 
increased permeability and increased production of cytokines and growth factors [48-50]. 
 
tPa
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Figure 4 Leukocyte-endothelial cell interactions on activated endothelial cells.  
Activated endothelial cells express adhesion molecules and chemokines that facilitate activation, adhesion, 
transmigration and differentiation of circulating leukocytes (mainly monocytes and T-cells) in the subintimal 
space. Selectins and their ligands are involved in the initial leukocyte rolling and tethering of leukocytes on the 
vascular wall. Integrins (VCAM and ICAM) induce firm adhesion at the endothelial cell surface. MCP-1 and other 
chemokines participate in the process of migration to the subintimal space, where the monocytes differentiate 
into macrophages.  
 
1.4.2 Cell adhesion molecules (CAMs) and endothelial and inflammatory markers 
CAMs, like intercellular adhesion molecule-1 (ICAM-1), E-selectin, and P-selectin, are 
expressed on activated endothelial cells as a response to vascular injury [48;49]. CAMs are 
induced by proinflammatory cytokines, like interleukin 6 (IL-6) and tumor necrosis factor  
(TNF, and facilitate leukocyte attachment to endothelial cells and migration into 
subintimal space of the arteries during vascular inflammation (figure 4). Monocyte 
chemoattractant protein-1 (MCP-1), also known as chemokine (C-C motif) ligand 2 (CCL-2), 
controls transendothelial migration and differentiation of monocytes into macrophages in 
subendothelial space and thereby mediates the recruitment of macrophages to the arterial 
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lesion [51]. TM is responsible for thrombin-induced activation of PC on the endothelial 
surface, and has been shown to suppress endothelial cell responses to inflammatory 
mediators. Moreover, expression of TM is reduced in endothelium overlying atherosclerotic 
plaques [52]. Increased levels of TM have been reported in various clinical conditions as CVD, 
diabetes, and endothelial injuries [53]. Enhanced secretion of VWF in response to 
inflammatory secretion has been shown to increase platelets interaction with endothelial 
cells [54]. 
C-reactive protein (CRP) has been considered to be a non-specific acute phase marker 
of tissue injury, infection or inflammation. Several studies have shown that CRP, in levels 
within normal range and as a marker of low-grade systemic inflammation, is a useful 
predictor of coronary artery disease (CAD) [55-57]. Whether CRP is a marker of 
atherosclerotic burden, or is directly involved in atherosclerosis is under investigation [58]. 
Moreover, it is unclear whether the relationship between CRP and inflammation is 
independent of other inflammatory markers. 
 
1.5 Venous thrombosis, epidemiology and risk factors 
The annual incidence of VT is 1 to 3 individuals per 1000 per year in a general population 
[59;60]. The major manifestations, deep vein thrombosis (DVT) and pulmonary embolism 
(PE) are associated with considerable acute and chronic morbidity. Acute death of PE occurs 
in 1-2 % of the patients, while post-thrombotic syndrome is a disabling sequele after DVT 
occurring in 15% to 50% of the patients [61]. More rarely thrombosis occurs in other veins, 
such as cerebral sinus veins, portal and liver veins, and upper extremity veins. Nevertheless, 
the diagnosis of VT can be difficult and remains a challenging clinical problem. The incidence 
of VT increases exponentially with age from approximately 1 per 100 000 in childhood, and 
increases to 1 per 100 for those over the age of 75 years. The annual incidence of VT was 
0.71 per 1000 in females between 40-59 years in a French study [59]. 
In the mid 19th century, Virchow postulated three major causes of thrombosis: 
changes in the vessel wall, alterations in blood flow, and changes in blood composition 
(hypercoagulability) [62]. This understanding of pathogenic factors is known as Virchow`s 
triad and is still considered useful to illustrate the pathogenesis of thrombosis. The 
biochemical and molecular basis of these components are progressively unraveled.  
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1.5.2 Inherited and acquired risk factors for venous thrombosis 
VT is considered to be a multicausal disease. Inherited and acquired risk factors may increase 
the risk of VT either in an additive or a synergistic fashion, and thereby contribute to the 
development of VT [63;64]. Many of the inherited risk factors for VT known today have a 
high prevalence in the general population. Many of the acquired risk factors are also 
common. A summary of known risk factors for VT is shown in table 2.  
 
ACQUIRED INHERITED MIXED/UNKNOWN 
Age Antithrombin deficiency High levels of factor VIII,  
Previous thrombosis Protein C deficiency High levels of factor IX 
Immobilization Protein S deficiency High levels of factor XI 
Trauma Factor V Leiden mutation (FVL) High levels of fibrinogen 
Plaster cast Prothrombin gene mutation  High levels of TAFI 
Major surgery  Low levels of TFPI 
Orthopedic surgery  APC resistance in absence of FVL 
Cancer  Hyperhomocysteinemia 
Medical disorders   
Antiphospholipid syndrome   
Oral contraceptives   
Hormone therapy   
Pregnancy   
Puerperium 
Overweight 
  
Table 2 Risk factors for venous thrombosis 
 
1.5.3 Hemostatic factors and risk of venous thrombosis  
Hereditary deficiencies of coagulation inhibitors, e.g., such as low levels of AT, PC, and PS are 
well established risk factors for VT [43;63;65]. Recently, low levels of TFPI was also shown to 
be associated with an increased risk of VT [66]. 
Factor VLeiden mutation is a major risk factor for VT, and is the most common cause of 
APC resistance [67]. However, an APC resistant phenotype is also seen in acquired conditions 
and with other genetic polymorphisms [42]. APC resistance, in the absence of the factor 
VLeiden mutation, is probably an independent risk factor for VT [68]. Several studies indicate 
that acquired APC resistance may be an important mechanism for the increased risk of VT 
associated with use of OC [43;44] and HT [69].  
There is evidence that elevated levels of procoagulant factors, such as FVIII, VWF, FIX, 
FX and FXI, exceeding the 90th percentile of the distribution of the clotting factors in the 
general population, are related to increased risk of VT. Studies on fibrinogen have been 
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inconclusive [65;70]. Moreover, increased levels of TAFI are associated with increased risk of 
VT [71], whilst this relation is uncertain for other fibrinolytic factors such as t-PA and PAI-I. 
 
1.6 Atherothrombosis, epidemiology and risk factors 
In developed countries CVD is the leading cause of morbidity and mortality for both men and 
women [72]. CAD, cerebrovascular disease and peripheral vascular disease are clinical 
complications of atherosclerosis, their common underlying pathophysiological process. 
These clinical complications are often triggered by arterial thrombosis, and the term 
atherothrombosis was introduced to integrate the chronic and acute aspects of the disease. 
Epidemiological studies have identified risk factors that are predictive of high 
incidence of disease [73;74]. Predisposing factors and factors associated with increased risk 
are shown in table 3. Clinical manifestation of CAD in women appears about ten years later 
than in men, but the impact of age is more important in women and they seem to have a 
higher case-fatality risk of CAD [72]. The majority of classical risk factors show no important 
gender specific differences, although there is evidence suggesting that hypertriglyceridemia, 
cigarette smoking, and diabetes mellitus are associated with higher relative risk in women 
than in men [74]. Furthermore, there are studies suggesting that some women tend to 
accumulate more risk factors and therefore end up with a higher relative risk than men at 
same age [75]. 
 
1.6.2 Atherosclerosis and inflammation 
It is now widely accepted that inflammation is involved in development and progression of 
atherosclerosis [49-51]. This is supported by biological data and by clinical studies showing 
correlations between circulating markers of inflammation and CVD. It is established that 
moderately elevated levels of high sensitivity CRP have been shown to be an independent 
risk factor of CAD [55-57]. In patients with myocardial infarction (MI), several studies have 
found that elevated levels of CAMs and selectins are associated with poorer outcome [48]. 
Moreover, levels of CAMs appear to be related to risk of CAD in healthy individuals [48]. 
Increased levels of TM have been reported in various clinical conditions, such as CVD, 
diabetes, and endothelial injuries [53]. Finally, studies have shown that increased 
concentrations of lipoprotein(a) (Lp(a)) are associated with higher risk of CAD [76]. 
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Risk factors (considered to be causally linked) Risk markers  
Smoking Elevated prothrombotic factors; fibrinogen, PAI-1 
Elevated LDLs Markers of inflammation 
Low HDL Elevated homocystein 
High blood pressure Elevated lipoprotein (a) 
Elevated glucose Low socioeconomic status 
Physical inactivity Physiological factors 
Obesity  
Diet  
 
Table 3 Risk factors and risk markers for cardiovascular disease 
 
1.7 Hormone therapy and risk of venous thrombosis 
Recent epidemiological studies and RCTs have shown that HT containing estrogen in 
conventional doses, e.g., 2 mg E2 or 0.625 mg CEE, is associated with an increased risk for VT 
[19-21;77-81], both in healthy women and in women with a history of VT [21]. The risk of VT 
is probably higher during the first year of use [21;79], and possibly more pronounced for 
users of combined estrogen-progestin HT than estrogen monotherapy [82;83]. Transdermal 
therapy does not seem to be associated with increased risk of VT [84;85]. A recent report 
showed no increased risk of VT in younger women receiving HT containing E2 [86]. 
Epidemiological studies have failed to detect significant differences in risk of VT between 
various estrogen doses [80;81;87], however these studies were not powered to detect such 
differences. One RCT has reported no excess risk of VT on low-dose E2 in a stroke prevention 
trial [88]. Only one case-control study has provided information on risk of VT on tibolone 
treatment [87], but the numbers of users were low. Data from RCTs are lacking. Raloxifene 
has been found to be associated with an increased risk of VT both in healthy women, and 
women with increased risk of CVD [31;89]. 
 
1.8 Hormone therapy and risk of atherothrombosis
Until the early 1990ies epidemiological studies suggested a cardioprotective effect of 
postmenopausal HT [17;18;90;91]. More recent RCTs reported that HT was associated with a 
modest, but significant increase in risk for CVD [19;20]. On the other hand, estrogen 
monotherapy is not associated with increased risk [83]. The discrepancies between these 
studies are under debate, and numerous hypotheses have been put forward to explain these 
contradictory results [92]. Lower risk of arterial thrombosis at lower doses of HT are 
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suggested by one RCT [88] and two epidemiological studies [91;93]. Grodstein et al have 
recently published observational data supporting lower risk for CVD in users of HT in 
younger women starting treatment near age of menopause [94]. Their results were similar 
across various doses of estrogen, and among women with several CVD risk factors. The risk 
of atherothrombosis by use of tibolone has been poorly evaluated, whereas studies on 
raloxifene have demonstrated conflicting results [31;95]. 
 
1.9 Menopause and changes in hemostatic factors  
Menopause is associated with minor changes in several coagulation factors, including minor 
increases in coagulation FVII, FVIII, and fibrinogen [96-103]. Minor increases in the 
coagulation inhibitors AT [96;104], PC [105], PS [106], and TFPI [66] are observed in healthy 
postmenopausal women, whereas markers of activated coagulation, e.g., F1+2 and TAT-
complexes seem to be unaffected by menopausal status [107]. Significant changes in the 
fibrinolytic factors including higher levels of PAI-1, and tPA are observed in postmenopausal 
women [103;108]. 
Studies have reported that menopause induces alterations in the cytokine profile. 
Reduced levels of transforming growth factor TGF) have been detected [109], but 
studies on TNFand IL-6 have shown conflicting results [109;110]. Levels of CAM and P-
selectin have been shown to be higher in postmenopausal women, as compared to 
premenopausal women [111], while levels of CRP have appeared to be unaffected by 
menopausal status [103;110]. 
 
1.10  Hormone therapy and effects on coagulation 
Several studies have evaluated the effects of HT on coagulation. The effects on markers of 
activated coagulation, on selected coagulation factors, coagulation inhibitors and markers of 
fibrinolysis are presented in table 4, 5 and 6. Only studies with a randomized design are 
included. Studies published both prior to (blue color) and later than the RET-study are 
included. 
 
1.10.1 Markers of activated coagulation 
There is now compelling evidence that oral HT containing conventional dose of estrogen is 
associated with increased levels of F1+2 [112-118]. Studies investigating the effects on D-
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dimer [114-121] and TAT complexes [113;116;118;122] have shown conflicting results. Two 
studies have demonstrated increased levels of D-dimer after 12 weeks of treatment with 
tibolone, but these changes did not sustain after 6 months [123;124]. Studies investigating 
the effect of tibolone on F1+2 are diverging [123;125;126]. Studies evaluating raloxifene have 
shown no significant changes in D-dimer, F1+2 and TAT complexes [127;128]. 
 
1.10.2 Coagulation factors 
Most studies using oral estrogen alone have reported increase in levels of FVII 
[113;116;117;129-131], whereas studies evaluating continuous, conventional-dose, 
combined HT have shown no effect on FVII [114;116;132], suggesting that progestin 
modifies the effects on FVII. Studies on E2 and progestin have even shown reduced levels of 
FVII [118;132]. Studies on FVIII and VWF have shown no change [113;114;117;118;130;133-
135]. There are few reports on other coagulation factors. 
RCTs on HT have reported inconsistent results on fibrinogen [113;114;117-
119;129;130;132;136-140], as opposed to RCTs on raloxifene which consistently have 
demonstrated decreased levels [127;141;142]. There are also few studies evaluating the 
effects of tibolone on procoagulant factors, but there is evidence for reduction in FVII, and 
no effect on FVIII [123;124;143]. Studies on the effects of tibolone on fibrinogen have been 
inconclusive [123;124;126;143].  
 
1.10.3 Coagulation inhibitors 
Oral HT affects all known pathways of coagulation inhibition. AT is lowered by 5-10% [112-
114;116;118;129;130;132;144], PC by 5-15% [116;118;132;144], PS by 0-5% [112;144] and 
TFPI by 10-30% [118;122;138;145;146]. There are limited data on the effects of tibolone. 
Some studies have found reduced levels of AT [124;125]. Studies on PC and PS are 
discordant [123;147]. Studies evaluating the effects of raloxifene on coagulation inhibitors 
have shown reduction in AT [128;148-150], whereas the effects on PC and PS have been 
poorly evaluated. No clinical studies evaluating the effects of raloxifene on TFPI are yet 
available.  
Recent studies suggest that HT, both conventional and lower doses, may reduce 
sensitivity to APC [69;134;151;152]. Treatment with raloxifene does not seem to alter the 
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sensitivity to APC [128;153], and there is only one study evaluating the effects of tibolone 
[123]. 
 
1.10.4 Fibrinolysis 
Several studies have reported evidence of increased fibrinolytic activity by use of HT, with 
decreased levels of PAI-1 [114-117;154-156], and increased levels of tPA [128]. In contrast to 
the other hemostatic markers, have the effects of tibolone on markers of fibrinolysis (e.g., 
PAI-1 and t-PA) been more extensively examined. Most studies have reported lowered PAI-1 
levels [123;124;126;157], and with a parallel decrease in t-PA [127;128;142]. OC have 
recently been shown to increase TAFI. The effects of HT is not clear, but one report found 
that HT decreased TAFI in women homozygous for the rare TAFI -438 A allele [71]. The 
effects of tibolone on TAFI levels have so far not been investigated. Studies on raloxifene 
have shown no effect on PAI-1 [127;128;142;158]. 
 
1.11  Hormone therapy and effects on endothelium and inflammation 
Several studies on postmenopausal HT in conventional doses, i.e., 2 mg E2 or 0.625 mg CEE 
have reported marked increase in CRP [135;138;155;159-164]. The increased CRP seems to 
be independent of elevated levels of IL-6 [160;162-165]. The effects of different progestins 
on CRP levels have been contradictory. The PEPI-trial showed no difference in CRP between 
different progestin components [135], whereas other studies have suggested that progestin 
attenuates the increase in CRP in a dose dependent manner [164]. Oral HT has been shown 
to reduce levels of ICAM, P-selectin, E-selectin, MCP-1 and Lp(a)[139;160;165-173]. 
Interestingly, some studies suggest that regimens with lower doses of HT, both with CEE and 
E2, to a lesser extent increased the CRP levels [174-176], whereas the favorable effects on 
endothelial markers were preserved. Transdermal treatment appears to have minor impact 
on markers of inflammation, as most studies both with or without different progestins have 
found no effect on CRP [117;177-179] and only minor lowering effects on CAMs [117;180]. 
Studies evaluating the effect of tibolone on CRP levels have been conflicting 
[125;181-184], but several reports have indicated that CRP levels are unaffected by 
raloxifene treatment [127;169;185;186].  
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2. Aims and hypotheses
Several studies have demonstrated that oral HT containing estrogen in conventional doses 
was associated with activation of coagulation and an increased risk of VT. We wanted to 
investigate whether lower dose of HT and other HT regimens had differential impact on 
relevant markers of the coagulation and fibrinolytic system, and on inflammation. The 
overall aim of this thesis was to compare the effects of different HT regimens on markers of 
activated coagulation, and to identify potential mechanisms for activated coagulation by 
analyzing markers of vascular disease. We were particularly interested in evaluating a 
possible relationship between dose of estrogen-progestin and impact on the various 
markers. Change in levels of D-dimer was the primary efficacy parameter in the RET- study. 
 
The aims of the thesis addressed in the different papers: 
Compare the impact of various HT regimens on markers of activated coagulation. 

 To evaluate a possible relationship between dose of estrogen-progestin and 
degree of activation of coagulation (paper I) 

 To compare the differential effects of HT, tibolone and raloxifene on coagulation 
activation (paper I) 
 
To elucidate possible mechanism(s) for differences in coagulation activation 

 To study the effect on coagulation factors, coagulation inhibitors, fibrinolytic factors, 
and the association with markers of activated coagulation (paper II)  

 To study whether the different regimens induce an APC resistant phenotype (paper 
III) 

 To examine the effects of the different regimens on CRP and other markers of 
inflammation, and their association with markers of activated coagulation (paper IV) 
 
To compare different routes of administration in women with high risk of vascular disease 

 To study the effects of oral and transdermal HT on CRP, and other markers of 
inflammation in women with high risk of thrombosis (paper V) 
  
 40 
 41 
3. Methods
This thesis is based on three single-centre RCTs; The Raloxifene, Estrogen and Tibolone (RET) 
study (papers I, II, III, and IV); The Estrogen in Venous Thromboembolism Trial (EVTET) and 
the Estrogen Women Atherosclerosis (EWA) study (paper V). Various biochemical markers 
and risk indicators related to venous and arterial disease were assayed. All the studies were 
conducted at the Department of Hematology at the Ullevål University Hospital Trust, Oslo.  
 
3.1 Study design, subjects and intervention
3.1.1. Raloxifene, estrogen and tibolone (RET) study 
This study was conducted from December 2002 to January 2005, and was designed as an 
open-label, randomized, comparative clinical study with four parallel groups. Change in 
levels of D-dimer was the primary efficacy parameter. In this study, 202 healthy 
postmenopausal women between the age of 45 and 65 years were included. Inclusion and 
exclusion criteria are described in detail in paper I. Women with a history of VT or 
symptomatic atherosclerotic disease or known thrombophilia were not included. The women 
were randomly allocated to four treatments; conventional-dose HT (2 mg E2 and 1 mg 
NETA), n=50; low-dose HT (1 mg E2 and 0.5 mg NETA), n=50; tibolone (2.5 mg tibolone), 
n=51; or raloxifene group (60 mg raloxifene hydrochloride), n=51. 
 
3.1.2. The Estrogen in Venous Thromboembolism Trial (EVTET) 
Between February 1996 and September 1998, 140 postmenopausal women were included in 
this double-blind placebo-controlled RCT. The women were under the age of 70 years, and 
had previously at least one verified VT, i.e., DVT or PE. The study design and main results 
have been reported in detail earlier [21]. The major outcome parameter, recurrent VT, 
occurred in eight women in the treatment group and in one woman in the placebo group. 
The study was terminated prematurely due to circumstantial evidence emerging during the 
trial. The women received treatment for 24 months with once daily either placebo tablets 
(n=69) or HT tablets containing 2 mg E2 and 1 mg NETA (n=71). 
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3.1.3. The Estrogen Women Atherosclerosis (EWA) study 
In this open controlled randomized study, 118 postmenopausal women were included 
between May 1995 and January 1997. The women were younger than 71 years and had 
angiographically verified CAD. The study design and primary outcome have been reported in 
detail earlier [206]. The women were randomized to receive either transdermal HT (n=60) 
given as unopposed transdermal E2 (50 g/24h), with sequential administration of 5 mg 
tablets of MPA once daily for 14 days every 3 months, or to a control group receiving no 
therapy (n=58).  
 
3.2 Data collection 
Details on data collection procedures in the three studies are described elsewhere; RET-
study (paper I), EVTET [21] and EWA [206]. Venous blood samples were collected before 
treatment (at baseline) and at follow-up visits. In the RET-study visits were scheduled after 2, 
6 and 12 weeks. In the EVTET-study the follow-up visits were after 3, 12 and 24 months, and 
in the EWA-study after 3 and 12 months. Women who discontinued before schedule due to 
adverse events, or withdrew their consent to participate, were followed until recovery of 
adverse event or until the time of consent withdrawal. 
 
3.3 Laboratory Assays/Measurements 
Citrated plasma was used to measure markers of activated coagulation (paper I), levels of 
coagulation factors, coagulation inhibitors and markers of fibrinolysis (paper II). Markers of 
inflammation (paper IV and paper V) were analyzed in serum. All markers were analyzed 
with enzyme-linked immunosorbent assays (ELISA). Commercial kits were used and run as 
described by the manufacturers. Further details are given in the separate papers of this 
thesis.  
The function of the APC system was analyzed by testing the effects of recombinant 
APC (rAPC) or thrombomodulin (rTM) on the Endogenous Thrombin Potential (ETP) as 
determined with the Calibrated Automated Thrombogram (CAT) assay. CAT was performed 
as described by Hemker et al [45]. To increase the reproducibility data were expressed as 
normalized APC sensitivity ratios (nAPCsr) by dividing the APCsr of test plasma with the same 
ratio obtained with PNP, either generated with rAPC or with rTM: 
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      (ETP+APC or TM/ ETP- APC or TM) test plasma  
 nAPCsr    =   
   (ETP+APC or TM/ ETP- APC or TM)PNP 
 
 
Thus, nAPCsr >1.0 reflects an APC resistance higher than in pooled normal plasma (PNP), 
which is consistent with an APC resistant phenotype. Further details are given in paper III. 
 
3.4. Statistics 
3.4.1. Demographic variables 
The continuous demographic variables were approximately normally distributed and were 
given as mean + standard deviation (SD), whereas categorical variables were presented as 
percentages. When comparing a continuous variable for more than two groups, the Kruskal-
Wallis test was used. Comparison of dichotomous variables between the groups was 
performed with the Chi-Square test. 
 
3.4.2 Descriptive statistics (The efficacy variables) 
The efficacy variables were given as mean and 95% confidence interval (CI) when 
approximately normally distributed, or as median and interquartile range (25th and 75th 
percentiles) if not. Treatment effects were calculated as the change, i.e., the difference from 
baseline to 2, 6 and 12 weeks, respectively, in the RET-study, and after 3 and 12 months in 
the EVTET and EWA-studies. Depending on the degree of skewness in the distribution of the 
variable, the treatment effects were presented as mean or median percent change with 95% 
CI. 
 
3.4.3 Significance testing 
Baseline values and values after treatment were compared by using a two-sided Wilcoxon 
Signed Rank test. Differences in mean or median percent change between two groups were 
analyzed using a two-sided t-test or two-sided Mann-Whitney test when appropriate. 
Primary comparisons in the RET-study were performed between the effects observed in the 
low-dose HT group and in each of the other treatment groups. When comparing the effects 
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for the whole treatment period, repeated measurements ANOVA (RMANOVA) were 
performed after logarithmic transformation (paper II and IV). In the RET-study findings with 
a p-value of <0.05 were considered significant. Due to the multiple comparisons performed 
in the EVTET and EWA-study, a 1% significance level was applied.  
 
3.4.4. Correlations and regression models 
Correlation between two variables was expressed as the Spearman correlation coefficient. In 
order to identify factors associated to change in D-dimer and CRP, linear regression analysis 
was used. When performing regression analysis, the basic assumption underlying such 
analysis, e.g., normality and linearity, were checked and found to be adequately met. 
Further details on the regression models are described in papers II and IV.  
 
3.4.5. Power calculation in the RET -study 
D-dimer was the primary efficacy parameter in this study. Based on results obtained in the 
EVTET study [118], we expected a difference in change in D-dimer between the 
conventional- and low-dose HT groups of 60 ng/mL (SD 90 ng/mL). Approximately 40 
individuals were needed in each treatment group in order to have 80% test power when 
comparing these two treatments. To correct for an expected 20% drop-out-rate we decided 
to include 50 women in each treatment group. 
 
3.4.6. Statistical packages 
Statistical analyses were performed using the Statistical Package for the Social Sciences 
version 11.0. (SPSS Inc., Chicago, Illinois, USA), except for the 95% CIs, which were calculated 
using Number Cruncher Statistical Systems (NCSS, Kaysville, Utah, USA). 
 
3.5 Ethical aspects 
The protocols were approved by the Regional Committee for Research Ethics in Health 
Region East, Norway, and by the Norwegian Medicines Agency. Written informed consent 
was obtained from each participant before inclusion. All three studies were carried out in 
accordance with the Helsinki declaration and Good Clinical Practice Guidelines. 
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Figure 5 Flow chart in the RET-study, showing the number of women screened, number and reasons 
for not being included in the study 
Patient contacts
n=358
Cardiovascular disease
n=8
Used HT
n=42
Various reasons
n=40
Randomized
n=202
Did not start treatment
n=2
Low-dose HT
n=46
Conv.-dose HT
n=46
Tibolone
n=48
Raloxifene
n=47
Withdraw their 
consent/advers events
Did not want HT
n=21
Age/menopause
n=39
Previous VT
n=6
Included in analysis after 12 weeks
n=187
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4. Main results 
 
4.1. Demographic characteristics in the RET-study 
Baseline data 
Demographic characteristics (age, body mass index [BMI], smoking habits, time since 
amenorrhea, and blood pressure) were similar at baseline for the four treatment groups 
(table 4). Two women, both in the raloxifene group, did not start treatment; one due to 
baseline mammography findings and one due to anxiety. During the study, 13 women 
stopped prematurely or withdrew their consent to participate. These dropouts and 
exclusions were evenly distributed between the groups (low-dose HT group; n=4, 
conventional-dose HT group; n=4, tibolone-group; n=3 and raloxifene group; n=2), and were 
due to known adverse effects of these regimens (table 5). 
 

Low-dose HT 
n=50 
Conv.-dose HT 
n=50 
Tibolone 
n=51 
Raloxifene 
n=51 
P-
value 
Age 
(years) 
54.7 + 5.1 56.1 + 3.6 55.1 + 4.7 56.5 + 4.8 0.16 
BMI 
(kgm-2) 
25.4 + 4.0 24.9 + 3.2 25.3 + 3.6 25.2 + 3.2 0.92 
SBP 
(mm Hg) 
128 + 17 124 + 14 126 + 14 127 + 16 0.64 
DBP 
(mm Hg) 
83 + 9 80 + 8 80 + 8 81 + 10 0.38 
Heart rate 
(beats min-1) 
69 + 8 69 + 8 70 + 10 70 + 12 0.97 
Smokers 
(percent) 
11 (22 %) 16 (32 %) 16 (31 %) 15 (30 %) 0.67 
Natural menopause 
(percent) 
41 (82 %) 36 (72 %) 40 (78%) 40 (80%) 0.65 
Years from 
menopause*(years) 
5.9 + 5.5 6.3 + 4.4 5.9 + 4.8 7.9 + 5.2 0.65 
 
Values were given as mean + SD or number and percentage of the women. The comparisons between baseline 
values were performed by using one-way ANOVA for continuous variables and Pearson Chi-Square for the 
categorical variable. BMI - body mass index; SBP - systolic blood pressure; DBP - diastolic blood pressure. 
*Years since menopause for women who had a defined onset of natural menopause, n=157 (78%).  
 
Table 7 Demographic characteristics.  
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
Low-dose HT 
n=4 
Conv.-dose HT 
n=4 
Tibolone 
n=3 
Raloxifene 
n=2 
Myocardial infarction - 1 - - 
Genital bleeding  1 3 - - 
Genital discharge  1 - - - 
Weight gain - - 1 - 
Edema 1 - - - 
Dizziness  - - 1 1 
Palpitations - - - 1 
Lost to follow up 1 - - - 
Elevation of bilirubin - - 1 - 
 
Table 8 Reasons for dropout in the RET-study 
 
4.1 Paper I 
Conventional-Dose Hormone Therapy (HT) and Tibolone, but not Low-Dose HT and 
Raloxifene, Increase Markers of Activated Coagulation 
In this paper the impact of the four differential HT regimens on the primary efficacy markers 
of the study, i.e., markers of activated coagulation, was evaluated. D-dimer, F1+2 and TAT-
complex were measured in 202 postmenopausal women after 2, 6 and 12 weeks of HT. D-
dimer increased markedly in the conventional-dose HT group, but remained unchanged in 
the low-dose HT group. This difference was statistically significant (RMANOVA p<0.0001). 
Tibolone was associated with a medium increase, whereas raloxifene was associated with a 
decrease in D-dimer levels. The changes in the raloxifene group differed significantly from 
the low-dose HT group (RMANOVA, p<0.0001), whereas the changes in the tibolone group 
did not. Changes in F1+2 showed a similar pattern for all four groups. However, the 
differences in F1+2 between the groups were only significant between the low-dose and the 
conventional-dose group (RMANOVA p=0.003). No significant differences in changes of 
thrombin-antithrombin complex were observed. 
 
4.2 Paper II 
Differential effects of conventional and low dose oral hormone therapy (HT), tibolone, and 
raloxifene on coagulation and fibrinolysis 
To elucidate the possible mechanisms for the activated coagulation, we investigated the 
effect of four HT regimens on selected clotting factors, coagulations inhibitors and 
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fibrinolytic factors. A multivariate regression model was used to determine their 
contribution to activation of coagulation. The conventional- and low-dose HT groups 
generally showed similar effects, i.e., reductions in both clotting factors and inhibitors, but 
the effects were more pronounced in the conventional-dose HT group. Compared with the 
low-dose HT group, those treated with tibolone showed more pronounced decreases in 
factor VII, less reduction of AT and PC, and even increased levels of PS and TFPI. As opposed 
to the low-dose HT group, in the raloxifene group the reductions in inhibitors were smaller. 
Moreover, in those allocated to raloxifene, reduced levels of fibrinogen were seen, whereas 
other coagulation factors and PAI-1 were increased. In the conventional-dose HT group a 
decrease in FVII antigen was significantly related to a decrease in D-dimer (6 weeks: 
p=0.029), whereas in the tibolone-group a decrease in TFPI was significantly related to an 
increase in D-dimer (12 weeks: p=0.025). In the raloxifene group reduction in fibrinogen was 
a significant predictor for reduction in D-dimer (6 weeks: p<0.0001, 12 weeks: p=0.001). 
 
4.3 Paper III 
Differential impact of conventional and low dose oral hormone therapy (HT), tibolone and 
raloxifene on functionality of the activated protein C system 
To study the possible mechanisms for the activation of coagulation, we analyzed the effect 
of the HT regimens on the sensitivity to APC in an assay with high sensitivity for hormonal 
changes. NAPCsr were determined in plasma collected at baseline and after 12 weeks, using 
a thrombin generation-based APC resistance test probed with either rAPC or by rTM. NAPCsr 
increased in both the conventional- and low-dose HT groups, consistent with reduced 
sensitivity to APC. The increase was slightly more pronounced in the conventional-dose 
group, but the difference between the two HT groups was not statistically significant (mean 
difference -0.13). We observed an increase in nAPCsr probed with rTM, but there were no 
differences between the conventional- and low-dose HT groups (mean difference -0.004). 
The sensitivity to APC was only marginally altered in those allocated to tibolone (mean 
difference 0.39 and 0.19 when probed with rAPC and rTM, respectively). Consequently, 
tibolone showed a different phenotype as compared with the low-dose HT group. A small 
increase in nAPCsr with both rAPC and rTM was seen in the raloxifene-group, but the 
increase was less than in the low-dose HT group (mean difference 0.23 and 0.13 when 
probed with rAPC and rTM, respectively). There was a negative correlation (r=-0.22, 
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p=0.002) between baseline values of D-dimer and nAPCsr generated with TM. In the low-
dose HT and tibolone groups the change in nAPCsr (with rAPC), was negatively correlated to 
the change in F1+2 (r=-0.37, p=0.01, and r= -0.35, p=0.02, respectively), whereas there was no 
correlation between these parameters in the conventional-dose HT and raloxifene groups. 
Neither was there a correlation between change in nAPCsr and change in D-dimer. 
 
4.4 Paper IV 
Differential impact of conventional dose and low dose hormone therapy (HT), tibolone and 
raloxifene on C-reactive protein (CRP) and other inflammatory markers 
In this paper, the impact of the four different HT regimens on CRP and other inflammatory 
markers was compared. Furthermore, the possible underlying mechanisms for changes in 
CRP and D-dimer were investigated. CRP increased in the conventional and low-dose HT 
group. These changes were more pronounced in the conventional-dose group (RMANOVA 
p=0.02). In addition, tibolone was associated with an increase in CRP, in contrast to 
raloxifene, which reduced CRP. None of these changes was significantly different from the 
low-dose HT group. Reduction in levels of Lp (a), ICAM, P-selectin, E-selectin and MCP-1 
were observed in all the four treatment groups. The changes were most pronounced for the 
conventional dose HT group, least pronounced for the raloxifene, whereas the changes in 
those allocated to tibolone and low-dose HT were intermediary. IL-6 decreased in all groups, 
but none of the changes was significantly different from the low-dose group. As opposed to 
the other groups, increased levels of TNF- and VWF ag were seen in the raloxifene group, 
and these changes were different from the low-dose group. The average increase in CRP was 
not accompanied by an increase in average IL-6 or TNF- or other markers, but women with 
large reductions in IL-6 had reduced increase in CRP. 
 
4.5 Paper V 
The effects of oral and transdermal hormone replacement therapy on C-reactive protein 
levels and other inflammatory markers in women with high risk of thrombosis 
In paper V, we compared the effects of oral and transdermal HT on CRP levels in women 
with high risk of thrombosis. In EVTET, additional inflammatory markers were assayed i.e., 
IL-6, TNFTGF, P-selectin, and VCAM-1. In the EVTET study, which included 140 women 
with a history of VT, oral HT was associated with strong activation of coagulation markers 
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and increased risk of recurrent VT [21]. No such associations were observed in the EWA-
study, where 118 women with established coronary artery disease were given transdermal 
HT [188]. Oral HT was associated with a significant increase in CRP after 3 months as 
compared with placebo (p=0.001). These changes sustained after 12 months. Among those 
allocated HT the median increase in CRP was higher in women who subsequently developed 
recurrent VT (median 328%, n=5, versus 54%, n=60). Levels of TNF and VCAM-1 decreased 
significantly in the HT group as compared to the placebo group (p=0.004 and p<0.001, 
respectively). There were no significant changes in levels of IL-6, TGF or P-selectin. On 
transdermal HT, no significant changes in CRP were observed after 3 and 12 months of 
treatment.  
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5. General discussion
5.1 Methodological considerations
5.1.1 Study design 
The RET study was an open-label, randomized clinical study, designed to compare the impact 
of four different hormone regimen on hemostasis. The main goal of a RCT is to compare 
groups of patients who only differ with respect to their treatment. The methods applied in 
these studies aim to eliminate bias. The random allocation ensured that treatment of the 
patients was carried out in an unbiased way. However, the open design in the RET-study did 
not allow us to rule out the bias connected to adherence and follow-up. However, both HT 
and raloxifene are frequently accompanied by minor side effects that render valid blinding 
difficult. Hence, the open design regarding treatment may on the contrary have contributed 
to the low dropout rate observed in our study (figure 5 and table 8). I would like to 
emphasize that the efficacy parameters in this study were changes in levels of biochemical 
markers, and not clinical end-points, such as clinical symptoms or frequency of disease. The 
overall aim of this study was to evaluate the impact of different HT on levels of activated 
coagulation and to identify potential mechanisms for activation. It could be argued that a 
more optimal design would have been a placebo-controlled study. However, this would 
entail significant increase in cost of conducting the study, which was not feasible with the 
limited funding of the study. Moreover, since all the biochemical markers were analyzed in a 
blinded fashion it is rather unlikely that the open design have influenced the test results.
Another potential weakness is the lack of an untreated control group in the RET-
study. A control group would have been beneficial in comparing our results in the low-dose 
group, to interpret these findings, and would probably have allowed us to conclude stronger 
on our findings in general. Nevertheless, the RET-study was designed to compare the four 
groups and the study was adequately powered (see sample-size calculation in Methods) to 
detect differences in change of D-dimer between the groups.  
Our data is limited to measuring impact of treatment after a given time period (12 
weeks in the RET-study), which does not allow us to conclude on the long term effects of 
these treatments. However, in the EVTET study the levels of D-dimer and other markers 
measured after 3 months sustained after 12 months.  
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5.1.2 Study population 
The RET study contains a heterogeneous population of healthy postmenopausal women; 
both new and prior users of HT were included. Although the groups were comparable 
regarding important demographic characteristics at baseline (table 7), we can not exclude 
the possibility that heterogeneity may have influenced the effects of treatment on various 
biochemical markers. 
Since the efficacy parameters were biochemical markers of vascular disease, we 
included healthy women with all degrees of climacteric symptoms in the study. The clinical 
indication for use was not recorded at inclusion and not measured nor evaluated during the 
study. However, the women included in our study probably reflect the population, who 
according to age and physical health were eligible for this treatment. Hence, our results are 
probably valid in the general population and have a potential for utilization in clinical 
practice.  
The EVTET study revealed an increased risk of recurrent VT by use of HT in women 
with previous VT [21]. These results clearly indicate that these women should avoid HT, and 
have thereby made substantial contribution to clinical decision making. The findings in the 
EWA and EVTET studies are limited to women with high risk of thrombosis. Due to increased 
risk of thrombosis in women with previous vascular disease demonstrated in EVTET and 
other recent studies, it now appears unethical to perform RCTs on these women. 
 
5.1.3 Intervention 
In order to assess the relation between dose and impact on the various biochemical 
markers, different doses of HT were studied. To more thoroughly evaluate a potential dose-
response relationship between the regimens containing E2 and NETA, we originally wanted 
to include a treatment group with even lower doses of estrogen and progestin, i.e., 0.5 mg 
E2 and 0.1 mg NETA. Unfortunately, preparations with lower doses were not available at the 
start of inclusion of this study.  
To study the underlying mechanism(s) for the activated coagulation, we compared tibolone 
and raloxifene with combined HT. This was based on the knowledge that these regimens 
have differential chemical structure and affinity for the various steroid receptors (see 
introduction). We postulated that these differences might reveal differences in impact on 
markers related to vascular disease.  
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The first study reporting differential risk of VT between oral and transdermal therapy 
was published during the time period we included women in the RET-study [84], and has 
later been confirmed by another case-control study [85]. The beneficial profile of 
transdermal therapy is supported by several studies on biochemical markers  
[117;151;152;177-180;188], and by our findings on markers of inflammation in women with 
high risk of thrombosis (paper V). 
In the RET-study the serum levels of E2, tibolone and raloxifene were not measured. 
The bioavailability of treatments in each group can therefore not be confirmed.  
 
5.1.4 Measurements 
The primary and secondary outcomes of the RET-study were biochemical markers of 
vascular disease. In the EVTET study, the increased risk of VT was related to a marked 
activation of coagulation, as measured by D-dimer and F1+2 [118]. These changes are 
suggested to be attributed to reduced levels of coagulation inhibitors, e.g., TFPI and acquired 
APC resistance [69]. The hypotheses of the RET-study were based on these results. Hence, 
the hemostatic factors assayed were mainly the same. The selection of biochemical markers 
related to endothelial function and inflammation was based on the circumstantial evidence 
in the field. 
To measure the different markers, mainly commercially available ELISA-kits were 
chosen. The ELISA methods are extensively tested and show low test-retest variability. 
Interassay coefficients of variation (CV) were between 2.1% and 12.9% for the various 
assays. All analyses were performed by skilled technical staff with long experience in our 
research laboratory. All assays were performed examiner-blind, and the samples were run in 
batch by the end of the study using a balanced set-up with an equal number of samples from 
the four different groups and with all samples for the same individual in each run. 
To evaluate the impact on functionality of the APC-system, a thrombin generation 
based APC-resistance test was used. This test has shown to be more sensitive to changes in 
hormonal changes than an APTT-based assay [207]. Even though CAT is an automated 
method, many of the processes involved are subjected to day-to-day variability. To increase 
the reproducibility, data were expressed as nAPCsr by dividing the APCsr of test plasma with 
the same ratio obtained with PNP (see Methods).  
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5.1.5.Statistical aspects 
Most of the variables had skewed distributions. The efficacy parameters were expressed as 
change from baseline in percent (%), with both negative and positive results, and logarithmic 
transformation was not possible. Non-parametric statistical methods were therefore 
applied. When the efficacy parameters were suitable for logarithmic transformation, 
parametric methods were chosen. To reduce the possibility of false positive results, we 
performed multivariate repeated measures analysis (RMANOVA). 
There are some inconsistencies in the statistical methods applied in the different 
papers. This is mostly due to different suggestions by reviewers during the peer-review 
process of publication. An example is the presentation of mean change in nAPCsr in paper III, 
as opposed to the other papers presenting median percent change of the efficacy variable. 
 
5.2 Discussion of main findings 
5.2.1 Impact of hormone therapy on activation of coagulation 
To our knowledge the RET-study was the first study to compare the impact of conventional- 
and low-dose HT containing E2 on markers of activation of coagulation. However, a 
relationship between dose of estrogen and effect on markers of activated coagulation was 
suggested in a small study from the early 1990-ies, which evaluated conventional (0.625 mg) 
and high dose (1.25 mg) CEE treatment [112]. More recently, another report of similar 
impact of dose of HT on coagulation from a study of oral HT containing CEE and MP was 
published [191].  
The findings of strong activation of coagulation in the conventional-dose HT group 
are in line with several other studies, in which an activation of the coagulation system has 
been observed on conventional-dose HT in both healthy women [112-117] and women with 
a history of VT [118]. Two recent studies investigating low-dose HT, containing 1 mg E2 
combined with gestodene or MP, have measured some activation of coagulation as 
determined with D-Dimer [154] or F1+2 [151]. Our finding, with no significant activation of 
coagulation in the low-dose HT group, is supported by a recent publication by Brosnan et al 
[197] utilizing the same low dose HT regimen as in our study, and by a study by Koh et al, 
which evaluated 0.3 mg CEE and MP [201] (table 4). 
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5.2.2 Impact of tibolone and raloxifene on activation of coagulation 
In paper I, we reported that tibolone, though to a lesser extent than conventional dose HT, 
also changed the overall hemostatic balance towards a more active state, with increased 
levels of D-dimer and F1+2. Similar effects of tibolone on D-dimer have been reported in two 
other studies [123;124], whereas another did not detect any changes [126]. Studies on F1+2 
have shown conflicting results (table 5) [123;125;126;201]. 
In the RET-study, we observed reductions in levels of D-dimer and a neutral effect on 
the other markers of coagulation activation in those allocated to raloxifene. Studies on 
raloxifene have shown no significant changes in D-dimer and TAT [127;128;158], and 
conflicting results regarding F1+2 (table 6) [127;142;158]. 
 
5.2.3 Impact of hormone therapy on coagulation 
Our study is in line with previous studies showing that oral HT affects all known pathways of 
coagulation inhibition [112-114;116;118;122;129;130;132;144-146;151;152]. Interestingly, 
the reductions in coagulation inhibitors, i.e., AT, PC and TFPI, were significantly less 
pronounced in the low-dose HT group. This dose-dependent effect on coagulation inhibitors 
may explain the diversity in activation of coagulation between low and conventional doses 
of HT. The relation between dose given and effects observed is also apparent for effects on 
coagulation factors and markers of fibrinolysis. Furthermore, we observed more pronounced 
reductions in sensitivity to APC in the conventional-dose HT group, but as opposed to many 
other markers the differences between the two HT groups were not statistically significant. A 
clearer relation to dose might have been revealed if lower doses of HT had been tested or if 
the sample size was larger. A post-hoc power calculation showed that the true difference in 
nAPCsr may be as large as 0.15 even if the observed difference between the groups in our 
study was non-significant (further details in paper III). 
 
5.2.4 Impact of tibolone and raloxifene on coagulation 
Our study is in line with other studies demonstrating reduced levels of AT after treatment 
with tibolone [123;124]. As recently demonstrated in another study [202], we observed 
reductions in PC, while others have shown no change [123;204]. In contrast to other studies 
showing reduction or no effect on PS [123;147;202;204], we observed increased free PS 
levels. Moreover, our study showed that tibolone increased TFPI activity, but had only minor 
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effects on the other TFPI assays. Tibolone only marginally altered nAPC-SR in our study, 
while others have demonstrated increased APC resistance ratio [123;202]. Consequently, 
compared with HT, tibolone shows a different phenotype with regard to APC. The 
differential effects on inhibitors between HT combinations and tibolone may be related to 
the androgenic properties of tibolone. This is supported by observations that men have 
higher levels of TFPI and PS than women. Moreover, androgens have been shown to 
increase expression of TFPI-genes in male macrophages [208]. 
Studies evaluating the effects of raloxifene on coagulation inhibitors have shown 
reduction in AT [128;148-150;158]. There are few reports on PC and PS, but our results are in 
line with the most well-powered of these [128]. No clinical studies evaluating the effects of 
raloxifene on TFPI are available. Studies evaluating the effect of raloxifene on APC resistance 
have shown conflicting results, i.e., either no effect or reduced sensitivity to APC as in our 
study [128;149;153]. 
 
5.2.5 Impact of hormone therapy on inflammation 
Our findings in the conventional-dose group are consistent with the results of several other 
studies, which have reported increased CRP levels on HT in equivalent doses, i.e., 2 mg E2 or 
0.625 mg CEE [135;138;155;161-163]. Other studies have reported no significant effects on 
CRP [165;174-176;209]. The discrepancy between these studies may be explained by the 
different type or dose of estrogen or progestin. Some of these studies suggest that regimens 
with lower doses of estrogen to a lesser extent increase the CRP levels [174-176], which are 
in line with our findings in the low-dose HT group. Moreover, our findings that transdermal 
HT induced no changes in CRP (paper V) are in agreement with other studies [179]. 
In concordance with other studies, we observed reductions in ICAM, P-selectin and E-
selectin in both HT-groups [160;165;167-171] suggesting an anti-inflammatory effect of HT 
on the endothelium. HT decreased levels of MCP-1 in our study, which is in line with other 
studies [166-168]. 
 
5.2.6 Impact of tibolone and raloxifene on inflammation 
Only a limited number of other studies have evaluated the effect of tibolone on CRP 
[125;181-184]. Our results are in line with the majority of these [181;184], and the studies 
showing no effects on CRP were small and thus probably underpowered [125;182]. Some 
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studies have indicated that CRP levels are unaffected by raloxifene treatment 
[127;169;185;186], whilst we observed small, but significant reductions. 
 
5.2.7 Proposed mechanism of activation of coagulation 
Despite extensive evaluation of the effects of HT and estrogen analogues on various markers 
of coagulation, the mechanism(s) for the increased risk of VT remain unresolved. Unraveling 
these mechanisms is challenging, due to the use of many different HT formulations and 
estrogen analogues, the many natural changes in hemostatic factors that occur in 
menopause, and the large number of prothrombotic factors of importance for thrombosis. 
Nevertheless, there is substantial evidence that conventional dose oral HT is associated with 
significant activation of coagulation. Importantly, it has recently been shown that even 
minor changes in clotting factors and coagulation inhibitors within normal ranges may 
account for such activation [210].  
A strong correlation between an increase in levels of markers of activated 
coagulation and reduction in coagulation inhibitors has previously been demonstrated 
[69;118]. Even though we observed marked changes in coagulation inhibitors, regression 
analysis did not reveal any clear-cut relation between changes in a single coagulation 
inhibitor and changes in D-Dimer. This may be explained by the complex mechanism for 
activation of coagulation, i.e., by the combined effects of reduction of coagulation inhibitors 
and changes in clotting factors.  
 
5.2.8 Proposed mechanism of inflammation 
The discrepancies between the increased risk of arterial thrombosis and the beneficial 
findings in biochemical markers and observational studies are under debate. Numerous 
hypotheses have been suggested to explain these contradictory findings [92]. The observed 
reductions of levels of endothelial adhesion molecules in all treatment groups in the RET-
study indicating an anti-inflammatory effect on the endothelial cells support the hypothesis 
of a beneficial influence of HT on vessel wall in younger women. 
There is evidence that inflammation is involved in the development and progression 
of atherosclerosis, and that high level of CRP is an independent risk factor for atherosclerotic 
disease [55-57]. However, it is still unclear whether high levels of CRP directly contribute to 
pathogenesis of atherothrombosis [58], and whether the relationship between CRP and 
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inflammation is independent of other inflammatory markers. Reports showing no effects on 
CRP by transdermal HT [179;211] support the hypothesis that the changes in CRP are due to 
a direct effect on the hepatic cells. Despite this, we observed positive associations between 
changes in CRP and IL-6, VWF ag, and MCP-1 in a multiple regression analysis, showing that 
women with a large reduction in IL-6 had reduced increase in CRP. Similar pattern was seen 
for VWF ag and MCP-1. Apparently, these findings are conflicting. However, in our opinion 
they raise the hypothesis that the changes in CRP may be a result of both inflammatory 
stimulation mediated by IL-6 and general metabolic hepatic activation of estrogen [160]. 
These observations are in agreement with a recent report from the PEPI-trial, showing a 
positive correlation between changes in CRP and changes in IL-6 after treatment with oral 
combined HT [212]. In contrast there was a negative correlation between changes in CRP 
and changes in IL-6 in the estrogen monotherapy, suggesting that the effect of IL-6 on CRP 
production is related to the progestin-component of the treatment, and that the CRP 
changes after estrogen monotherapy are generated through a different pathway [212]. 
Moreover, reductions in IL-6 and VWF ag were significant predictors for reductions in CRP in 
the raloxifene group. 
 
5.2.9 Link between coagulation and inflammation 
Until recently, arterial thrombosis and VT have been considered unlinked disorders. There is 
now growing evidence for a possible association between arterial thrombosis and VT [213]. 
Recent reports suggest that these conditions share several risk factors and that their etiology 
are related to a combination of factors involved both in inflammation and thrombosis [213-
215]. Several components of the vascular endothelium and coagulation factors have been 
suggested to be the link between inflammation and coagulation [52;216]. In a multiple 
regression analysis, we found that increases in CRP and IL-6 were significantly related to 
increase in D-dimer, both in the tibolone and the conventional-dose HT groups. Moreover, 
reductions in CRP and VWF ag were significant predictors for reductions in D-dimer in the 
raloxifene group. 
 
5.3 Clinical implications 
The many studies evaluating different doses and types of estrogen, different progestin 
formulation, and various routes of administration partly show conflicting results, which 
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render the clinical interpretations of these observations difficult. These divergent results 
might also be related to the age of the women, duration of treatment, coexistence of 
associated diseases, especially presence of atherothrombotic disease and other risk factors 
for hypercoagulability. 
 
5.3.1. Biochemical markers and clinical importance 
Several biochemical markers have been suggested to be associated with an increased risk of 
thrombosis [217]. First, it is important to emphasize that these markers are risk markers and 
not necessarily risk factors, involving causality. Nevertheless, in the EVTET study it was 
shown that the increased risk of VT was related to a marked activation of coagulation [118], 
and these changes were suggested to be attributed to reduced levels of coagulation 
inhibitors [69]. The mechanisms involved in thrombosis, i.e., the clinical and biological 
relevance of altered levels of various markers remains to be confirmed in RCTs. Additionally, 
the understanding of the mechanisms by which estrogen change the factors involved in 
thrombosis are incomplete (see Discussion of main findings). 
Although the results from the RET-study indicate a differential effect of these four 
regimens on markers of vascular disease, the relationship between changes in these markers 
and risk of thrombosis remains unresolved. Our study was not designed to evaluate this 
issue; hence, our data do not provide any evidence for a relation between markers of 
vascular disease and thrombosis. 
 
5.3.2 Relation to dose of hormone therapy 
Only two epidemiological studies evaluating the risk of VT have examined dose relations 
[81;87]. Both these studies indicated an increased risk of VT with increasing dose of 
estrogen. However, the results did not reach statistical significance and must be interpreted 
with caution. Daly et al. included women using conventional-dose HT (0.625 mg CEE) in their 
low-dose group [87]. However, there is epidemiological evidence that lower oral doses may 
be associated with reduced risk of arterial thrombosis [91;93].  
RCTs evaluating the risk VT of oral HT have almost uniformly utilized preparations 
containing either 0.625 mg CEE or 2 mg E2 [19-21]. RCTs evaluating the risk of VT on low-
dose HT are lacking, except for the stroke-study of Viscoli et al. [88], where no excess risk of 
stroke, MI or VT was found. Moreover, two epidemiological studies have observed reduced 
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risk of arterial thrombosis on lower dose HT [91;93]. These findings fit well with the 
favorable effects that low-dose HT exert on inflammatory and endothelial markers [218], 
and the differential impact of the conventional and low-dose HT observed on hemostatic 
markers in the RET study. Furthermore, these findings indicate that low-dose HT has a more 
favorable risk-to-benefit profile than conventional-dose HT. Finally, it raises the question 
whether treatment with low-dose HT would yield different results regarding the risk of CVD 
in large RCTs. To address this question, RCTs utilizing low dose HT evaluating clinical end-
points are warranted.  
 
5.5.3 Impact of progestin 
There is no data showing that progestin treatment alone used as OC or in intra uterine 
device (IUD) increases the risk of VT [219;220]. Although progestin-only pills seem to have 
minor impact on coagulation [221;222], it has been demonstrated in studies on different OC 
that different progestins attenuate the effects of estrogen on coagulation differently 
[44;221;223-226]. Moreover, there is evidence that OC containing different third-generation 
progestins increases the risk of VT [227;228]. Hence, the differential impact of the 
conventional and low-dose HT on most of the markers evaluated in the RET-study might be 
attributed both to the differential dose of estrogen and/or progestin utilized in the 
regimens.  
 
5.3.4. Tibolone and raloxifene 
The clinical implications of our findings on tibolone and raloxifene are not obvious. To our 
knowledge, no well-powered epidemiologic study nor clinical trial evaluating tibolone and 
the risk of VT has been performed [87]. However, a trial evaluating the effect of tibolone on 
the risk of vertebral fractures found that tibolone was associated with an increased risk of 
stroke [229]. Although our results showing that tibolone activates coagulation may indicate 
that tibolone has prothrombic properties, further clinical studies are required to conclude on 
the risk of VT with tibolone. 
RCTs have shown that raloxifene is associated with an increased risk of VT [29-31], 
which may be comparable to that observed on conventional-dose HT. The risk of CVD 
associated with raloxifene are under debate [31;95;230;231]. In a large RCT, a subgroup of 
women at risk of CVD showed a reduction in coronary and cerebrovascular events when 
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assigned to raloxifene [95]. Since raloxifene in our study was not associated with activation 
of coagulation, other mechanisms for triggering thrombosis may be involved. 
 
5.3.5 C-reactive protein - a predictor of venous thrombosis? 
Significance of the proinflammatory effects of HT is controversial, and the clinical 
implications of an increase in CRP following HT are under debate. Based on the atherogenic 
properties of CRP [58] it has been suggested that the CRP increase induced by estrogen over 
many years may contribute to progression of atherosclerosis. It has been proposed that this 
partly can explain the observed increased risk of CVD by use of HT. However, in the WHI-
study, the increased levels in CRP were not associated with increased risk of CHD [163]. In 
the EVTET-study, of women with a history of previous VT, the women who subsequently 
developed recurrence had a markedly higher increase in CRP at three months than those 
who did not (paper V). This finding must be interpreted with care because of the low 
number of cases (n=5). Nevertheless, our findings suggest that CRP might be a clinical 
predictor in recurrent thrombosis, as has been reported in an observational study [232].
 
5.3.6 Relation to route of administration 
Transdermal application yields minimal effects on hemostatic and inflammatory markers 
[117;152;154;177-179;189] and is most probably not associated with increased risk of 
thrombosis [84;85]. Our findings, that oral HT is associated with a marked and rapid increase 
in CRP in women with high risk of thrombosis, whereas transdermal treatment is not, 
support the notion that transdermal therapy is safer. The increases in CRP in our studies 
were not accompanied by increases in IL-6, TNF or other inflammatory markers, neither in 
healthy women (paper IV) nor in women with a high risk of thrombosis (paper V), indicating 
that this increase is due to hepatic activation and not to a general inflammatory response. 
Nevertheless, in the RET-study (paper IV) we observed a positive association between 
increase in CRP and IL-6, raising the hypothesis that the changes in CRP may be a result of a 
combined effect of both an effect of IL-6 and a direct effect on the liver cells (se Discussion 
of main findings).  
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Main Conclusions

 The various HT regimens and raloxifene exerted differential effects on markers of 
activated coagulation, coagulation factors, inhibitors and fibrinolytic factors, and 
markers of inflammation. 

 Compared with the conventional-dose HT group, the low-dose HT group showed 
minor changes, suggesting a relation between dose of estrogen-progestin and effect 
on the various markers. 

 Estrogen-progestin therapy induced an APC resistant phenotype, whereas tibolone 
and raloxifene only marginally altered the sensitivity to APC. 

 Despite the marked changes in coagulation inhibitors, the regression analyses did not 
reveal any clear-cut relation between changes in a single coagulation inhibitor and 
changes in D-Dimer. 

 An increase in average IL-6, TNF- or other markers did not accompany the average 
increase in CRP, but women with large reductions in IL-6 had reduced increase in 
CRP.  

 In women with high risk of thrombosis, oral HT containing E2, but not transdermal 
therapy was associated with a marked and rapid increase in CRP. The increase in CRP 
by oral treatment was not associated with increases of other inflammatory markers.  
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Future Perspectives
Contrary to earlier epidemiological studies suggesting protective effects of HT on CVD 
[90;91], recent RCT have demonstrated that HT in conventional doses induce a modest, but 
increased risk of CAD and VT [19-21;77-81]. It has also been shown that the increased risk of 
VT was related to a marked activation of coagulation [118] and these changes are suggested 
to be attributed to reduced levels of coagulation inhibitors [69]. Moreover, it has recently 
been shown that even minor changes in clotting factors and coagulation inhibitors within 
normal ranges may account for such activation [210]. These data support the hypothesis of a 
threshold by which estrogens may induce activation of coagulation, which might trigger 
thrombosis. Our results showing no impact of low-dose HT on markers of activated 
coagulation challenge the validity of the results from large RCTs utilizing conventional-dose 
HT, and it may be hypothesized that a lower-dose might have given lower risk of thrombosis. 
To address this question, RCTs utilizing low-dose HT evaluating clinical end-points are 
needed.  
Unfortunately, no preparations with even lower doses of HT (ultralow) were available 
at the start of inclusion of the RET study. Recently, regimens with ultralow-dose of E2 and 
NETA have demonstrated its effectiveness on climacteric symptoms [233]. In order to find 
the regimen with the least potential harm, and further investigate the relationship between 
doses of estrogen/progestin, evaluating these regimens’ effects on hemostatic markers are 
warranted.  
The mechanism of HT-induced increased CVD is under investigation. Although no 
single coagulation factor has shown to be able to detect future thrombosis, multiple changes 
in hemostatic variables are measured and thrombogenic mechanisms have shown to be of 
importance. To investigate other possible candidates to explain the effects of HT on vascular 
disease a micro-array analysis in a subpopulation of the women in the RET-study has been 
performed. Hopefully, this analysis will contribute to elucidate the complex gene regulatory 
effects of ER-ligands and provide new insight on the mechanisms of thrombosis. 
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